ALNY halted on Oct 29 2026 at $195.67
ALNY-15.8%on Thu Oct 29 2026
Alnylam Pharmaceuticals, Inc. was down 15.8% on the day at $195.67, ranked #93 on 14.0× its usual five-minute volume, when TapeRank recorded this trading halt at 09:35 ET during regular hours when it was halted. TapeRank recorded 2 events for ALNY that day, between 09:35 and 12:10 ET, and each is in the timeline below.
THE DAY ON THE LIST · 2 EVENTS
- 09:35 ETHALT · REGULAR
HALTED AT $195.67 · ▼ 15.8% ON THE DAY · 14.0× 5M RVOL · RANK #93
No verdict was committed for this event.
THE ROW AND SESSION LEVELS AT 09:35 ET
LAST195.67DAY▼ 15.8%5 MIN▲ 6.92%5M RVOL14.0×5M $VOL$44.2MFLOAT*133.8MRANK#93SESSIONREGULARVWAP190.10HOD242.00LOD179.87OR HIGH195.67OR LOW179.87PREV CLOSE232.40PM HIGH242.00PM LOW185.00GAP▼ 20.14%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
- 12:10 ETMOVER · REGULAR
$185.72 · ▼ 20.1% ON THE DAY · 9.5× 5M RVOL · RANK #4
STRETCHEDCONFIDENCE4/5Alnylam is down 20.6% despite reporting strong quarterly revenue growth, an EPS and sales beat, and reaffirmed full-year sales guidance. The negative reaction is likely tied to slower-than-anticipated patient-start conversion and reimbursement concerns, but the magnitude of the decline is far larger than the disclosed operational negatives.
WHYDown 20.6% is outsized relative to a quarterly beat and reaffirmed guidance, with only qualitative adoption and reimbursement risks disclosed.ANALYZED 12:12 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 12:10 ET
LAST185.72DAY▼ 20.1%5 MIN▼ 0.93%5M RVOL9.5×5M $VOL$10.3MFLOAT*133.8MRANK#4SESSIONREGULARVWAP193.59HOD242.00LOD179.87OR HIGH195.67OR LOW179.87PREV CLOSE232.40PM HIGH242.00PM LOW185.00GAP▼ 20.14%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
NO VERDICT MEANS THE MODEL HAD NOT REACHED THE NAME BEFORE THE EVENT WAS FINALIZED, OR ITS ANSWER HEDGED AND WAS WITHHELD. NOTHING WAS FILLED IN AFTERWARDS.
THE SESSION
- 09:30 ETOpened at $185.59, -20.1% on the previous close of $232.40
- 09:35 ETHalted (LUDP); resumed 09:40 ET, after 5 minutes
- 10:24 ETRegular-session high, $202.37
- 13:39 ETRegular-session low, $172.31
- 15:59 ETLast trade of the regular session, $173.74, -25.2% on the previous close of $232.40
- Volume: 10.9M shares in regular hours, 67K before the open
ALNY opened at $185.59, already 20.1% below the previous close, then climbed to $202.37 before a five-minute LUDP halt at 09:35 ET. After resuming, the stock reversed lower, reaching $172.31 at 13:39 ET and ending the regular session at $173.74, down 25.2% from the prior close, on 10.9M shares. TapeRank tied the move to the earnings update: Alnylam beat quarterly EPS and sales expectations and reaffirmed full-year sales guidance, but disclosed slower patient-start conversion and reimbursement concerns; TapeRank judged the decline stretched relative to those negatives.
WRITTEN THU OCT 29 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 09:39 ETAlnylam Pharmaceuticals Q3 2026 Earnings Call TranscriptBenzinga
- 08:20 ET10-Q — Quarterly reportSEC 10-Q
- 08:16 ET8-K — Results of Operations and Financial Condition; Financial Statements and ExhibitsSEC 8-K
- 08:03 ETAlnylam Pharmaceuticals Q3 Adj. EPS $16.26, Sales $1.458B Beat $1.434B EstimateBenzinga
- 08:01 ETAlnylam Pharmaceuticals Affirms FY2026 Sales Guidance of $5.275B-$5.725B vs $5.471B EstBenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list